文献速递泌尿生殖腹部MR

酰胺质子转移成像与扩散加权成像评估膀胱癌Ki-67、p53及PD-L1表达的对比分析

Comparative Analysis of Amide Proton Transfer and Diffusionweighted Imaging for Assessing Ki-67, p53 and PD-L1 Expression in Bladder Cancer.
PubMed 文献 · Acad Radiol · 2024-10-05

本研究纳入88例疑似膀胱癌患者行术前多参数MRI,评估酰胺质子转移(APT)成像评估Ki-67、p53及PD-L1状态的效能并与扩散加权成像(DWI)对比。APT信号与三种分子标志物均显著相关,高Ki-67、高p53及PD-L1阳性膀胱癌的MTRasym值更高,且APT诊断效能优于DWI。

要点

  • 膀胱癌高Ki-67、高p53及PD-L1阳性者MTRasym值更高,ADC更低。
  • p53状态MTRasym阈值1.27%时敏感度95%、特异度60%、AUC 0.781。
  • PD-L1状态MTRasym阈值1.90%时敏感度88%、特异度92%、AUC 0.859。

核心结论

  • APT可能显著提升膀胱癌术前侵袭性评估并为靶向免疫治疗决策提供信息,效能优于DWI。

研究设计与样本

  • 连续纳入疑似膀胱癌患者行术前多参数MRI,共88例(72±10岁,77例男性),由两名放射科医师测量MTRasym和ADC并评估观察者间一致性。

关键影像表现/征象

  • 高Ki-67表达膀胱癌MTRasym为1.89%(0.73%)vs 低表达1.23%±0.26%,P<0.001。
  • 高p53表达膀胱癌MTRasym为1.63%(0.56%)vs 低表达1.24%(0.56%),P<0.001。
  • PD-L1阳性膀胱癌MTRasym为2.02%(0.81%)vs 阴性1.48%(0.38%),P<0.001。
  • 高Ki-67表达膀胱癌ADC为1.06×10-3 mm2/s(0.32×10-3 mm2/s)vs 低表达1.38×10-3 mm2/s(0.39×10-3 mm2/s),P<0.001。

诊断标准与关键数值

  • p53状态:MTRasym阈值1.27%,敏感度95%、特异度60%、AUC 0.781。
  • PD-L1状态:MTRasym阈值1.90%,敏感度88%、特异度92%、AUC 0.859。

临床应用与阅片要点

  • APT的MTRasym值与Ki-67、p53及PD-L1水平显著相关(P<0.05),可用于术前无创评估膀胱癌分子特征。
  • APT在评估膀胱癌侵袭性及免疫治疗相关标志物方面效能优于DWI。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: To evaluate amide proton transfer (APT) imaging for assessing Ki-67, p53 and PD-L1 status in bladder cancer (BC) and compare its diagnostic efficacy with that of diffusion-weighted imaging (DWI).

MATERIALS AND METHODS: Consecutive patients suspected of BC were recruited for preoperative multiparametric MRI. APT signal was quantified by asymmetric magnetization transfer ratio (MTRasym). MTRasym and apparent diffusion coefficient (ADC) were measured by two radiologists, with interobserver agreement assessed. Spearman's correlation analyzed MTRasym values and molecular markers. The Whitney U test evaluated MTRasym and ADC variation based on molecular marker status. Optimal cutoff points were determined using area under the curve (AUC) analysis.

RESULTS: 88 patients (72 ± 10 years; 77 men) with BC were studied. MTRasym values were significantly correlated with Ki-67, p53 and PD-L1 levels (P < 0.05). Higher MTRasym values were found in high Ki-67 expression BCs (1.89% [0.73%] vs. 1.23% ± 0.26%; P < 0.001), high p53 expression BCs (1.63% [0.56%] vs. 1.24% [0.56%]; P < 0.001) and positive PD-L1 expression BCs (2.02% [0.81%] vs. 1.48% [0.38%]; P < 0.001). Lower ADCs were found in high Ki-67 expression BCs (1.06 ×10-3 mm2/s [0.32 ×10-3 mm2/s] vs. 1.38 ×10-3 mm2/s [0.39 ×10-3 mm2/s]; P < 0.001). For p53 status, an MTRasym threshold of 1.27% had 95% sensitivity, 60% specificity, and AUC of 0.781. For PD-L1 status, a 1.90% threshold had 88% sensitivity, 92% specificity, and AUC of 0.859.

CONCLUSION: APT may significantly enhance the preoperative assessment of BC aggressiveness and inform targeted immunotherapy decisions, with performance superior to DWI.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Li JL, Xu Y, Xiang YS, et al. Comparative Analysis of Amide Proton Transfer and Diffusionweighted Imaging for Assessing Ki-67, p53 and PD-L1 Expression in Bladder Cancer. Acad Radiol. 2024. PMID: 39370312. doi:10.1016/j.acra.2024.09.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。